The Technical Analyst
Oyster Point Pharma, Inc. [OYST]
Exchange: NASDAQ Global Select Sector: Healthcare Industry: Biotechnology
Oyster Point Pharma, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.00% $11.17
/ 30 des 2022 @ 16:00
| RATING 2023-02-03 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/21 | 3/21 | 4/21 | 1/22 | 2/22 | 3/22 | |
| Revenue | n/a | n/a | ||||
| Gr.Profit | n/a | n/a | ||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| N/A |
| Company: PE 0 | industry: PE 0 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 10.91 - 11.43 ( +/- 2.34%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-01-03 | Invopps Gp Iv, L.l.c. | Sell | 1 850 818 | Common Stock, par value $0.001 per share |
| 2023-01-03 | Invopps Gp Iv, L.l.c. | Sell | 1 850 818 | Common Stock, par value $0.001 per share |
| 2023-01-03 | Versant Venture Capital Vi, L.p. | Sell | 1 003 658 | Common Stock |
| 2023-01-03 | Versant Venture Capital Vi, L.p. | Sell | 1 003 658 | Common Stock |
| 2023-01-03 | Behbahani Ali | Sell | 10 066 | Common Stock |
| INSIDER POWER |
|---|
| -97.61 |
| Last 100 transactions |
| Buy: 1 389 418 | Sell: 22 126 304 |
Forecast:
01:40 - $11.68
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $11.17 (0.00% ) |
| Volume | 2.09 mill |
| Avg. Vol. | 0.418 mill |
| % of Avg. Vol | 500.11 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For OYST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
OYST
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
Latest Press Releases
2022-11-02 16:02:00 - Press Release
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
Conference call and webcast scheduled for november 10, 2022, 4:30 p.m. et conference call and webcast scheduled for november 10, 2022, 4:30 p.m. et
2022-09-27 08:00:00 - Press Release
Oyster Point Pharma To Present New Scientific Analyses At World Cornea Congress Viii
Two featured presentations will include a post-hoc analysis of tyrvaya® (varenicline solution) nasal spray and tear film cytokine research two featured presentations will include a post-hoc analysis of tyrvaya® (varenicline solution) nasal spray and tear film cytokine research
2022-08-25 08:00:00 - Press Release
Oyster Point Pharma To Present Analyses At The Women In Ophthalmology Summer Symposium
Princeton, n.j., aug. 25, 2022 (globe newswire) -- oyster point pharma, inc. (nasdaq: oyst), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of analyses at the women in ophthalmology (wio) summer symposium, which is taking place in monterey, california from august 25-28, 2022.
2022-08-08 16:03:00 - Press Release
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
Conference call and webcast scheduled for august 11, 2022, 4:30 p.m. et
2022-05-03 16:01:00 - Press Release
Oyster Point Pharma To Report First Quarter 2022 Financial Results On May 5, 2022
Conference call and webcast scheduled for may 5, 2022, 4:30 p.m. et conference call and webcast scheduled for may 5, 2022, 4:30 p.m. et
Latest News
2022-11-10 18:48:16 - Zacks Investment Research
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates
OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of 9.87% and 24.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-11-07 20:53:52 - Pulse2
Why Viatris (VTRS) Is Buying Oyster Point (OYST)
2022-11-02 16:02:00 - GlobeNewsWire
Oyster Point Pharma To Report Third Quarter 2022 Financial Results On November 10, 2022
Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET Conference Call and Webcast Scheduled for November 10, 2022, 4:30 p.m. ET
2022-09-27 08:00:00 - GlobeNewsWire
Oyster Point Pharma to Present New Scientific Analyses at World Cornea Congress VIII
Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research Two Featured Presentations will Include a Post-Hoc Analysis of TYRVAYA® (varenicline solution) Nasal Spray and Tear Film Cytokine Research
2022-08-25 08:00:00 - GlobeNewsWire
Oyster Point Pharma to Present Analyses at the Women in Ophthalmology Summer Symposium
PRINCETON, N.J., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced the presentation of analyses at the Women in Ophthalmology (WIO) Summer Symposium, which is taking place in Monterey, California from August 25-28, 2022.
2022-08-13 15:45:57 - Seeking Alpha
Oyster Point Pharma, Inc. (OYST) CEO Dr. Jeffrey Nau on Q2 2022 Results - Earnings Call Transcript
Oyster Point Pharma, Inc. (NASDAQ:OYST ) Q2 2022 Results Conference Call August 11, 2022 4:30 PM ET Company Participants Arty Ahmed - Vice President, Investor Relations Dr. Jeffrey Nau - President and Chief Executive Officer Dan Lochner - Chief Financial Officer and Chief Business Officer Michael Campbell - Senior Vice President and Head of Commercial Conference Call Participants Patrick Dolezal - LifeSci Capital Ken Cacciatore - Cowen Joe Catanzaro - Piper Sandler Daniil Gataulin - Chardan Operator Good day, and thank you for standing by. Welcome to the Oyster Point Pharma Second Quarter 2022 Earnings Conference Call.
2022-08-11 18:49:20 - Zacks Investment Research
OYSTER PT PHARM (OYST) Reports Q2 Loss, Lags Revenue Estimates
OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of -14.02% and 2.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-08-08 16:03:00 - GlobeNewsWire
Oyster Point Pharma To Report Second Quarter 2022 Financial Results On August 11, 2022
2022-07-21 11:39:20 - Zacks Investment Research
Wall Street Analysts Think OYSTER PT PHARM (OYST) Could Surge 423%: Read This Before Placing a Bet
The consensus price target hints at a 423.5% upside potential for OYSTER PT PHARM (OYST). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2022-06-30 10:23:35 - Seeking Alpha
Oyster Therapeutics: State Of Business Is Confounding
OYST has an approved product that is highly competitive against a blockbuster drug. They seem to have executed commercialization pretty well, except in the bottom line.